Ocular characteristics and complications in patients with osteogenesis imperfecta: a systematic review.

Sanne Treurniet, Pia Burger, Ebba A E Ghyczy, Frank D Verbraak, Katie R Curro-Tafili, Dimitra Micha, Nathalie Bravenboer, Stuart H Ralston, Ralph de Vries, Annette C Moll, Elisabeth Marelise W Eekhoff

Journal: Acta ophthalmologica 2022;100(1):e16-e28

PMID: 34009739

Abstract

PURPOSE

Osteogenesis imperfecta (OI) is a rare inherited heterogeneous connective tissue disorder characterized by bone fragility, low bone mineral density, skeletal deformity and blue sclera. The dominantly inherited forms of OI are predominantly caused by mutations in either the COL1A1 or COL1A2 gene. Collagen type I is one of the major structural proteins of the eyes and therefore is the eye theoretically prone to alterations in OI. The aim of this systematic review was to provide an overview of the known ocular problems reported in OI.

METHODS

A literature search (in PubMed, Embase and Scopus), which included articles from inception to August 2020, was performed in accordance with the PRISMA guidelines.

RESULTS

The results of this current review show that almost every component of the eye could be affected in OI. Decreased thickness of the cornea and sclera is an important factor causing eye problems in patients with OI such as blue sclera. Findings that stand out are ruptures, lacerations and other eye problems that occur after minor trauma, as well as complications from standard surgical procedures.

DISCUSSION

Alterations in collagen type I affect multiple structural components of the eye. It is recommended that OI patients wear protective glasses against accidental eye trauma. Furthermore, when surgery is required, it should be approached with caution. The prevalence of eye problems in different types of OI is still unknown. Additional research is required to obtain a better understanding of the ocular defects that may occur in OI patients and the underlying pathology.

© 2021 The Authors. Acta Ophthalmologica published by John Wiley & Sons Ltd on behalf of Acta Ophthalmologica Scandinavica Foundation.

Address: Department of Internal Medicine, Section Endocrinology, Amsterdam Bone Center, Amsterdam University Medical Center, Amsterdam, The Netherlands.; Department of Ophthalmology, Amsterdam University Medical Center, Amsterdam, The Netherlands.; Department of Clinical Genetics, Amsterdam Movement Sciences, Amsterdam University Medical Center, Amsterdam, The Netherlands.; Department of Clinical Chemistry, Bone and Calcium Metabolism Lab, Amsterdam University Medical Center, Amsterdam, The Netherlands.; Centre for Genomic and Experimental Medicine, MRC Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, UK.; Medical library, Vrije Universiteit, Amsterdam, The Netherlands.
Bant logo

© Copyright 2026, Nutrition Evidence

NED wishes to thank the following organisations for their support:

We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.